Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis

Federal University of São Paulo

Status: Completed

Conditions: Conjunctivitis, Viral; Adenoviridae Infections

Treatments: Drug: Ganciclovir; Drug: Artificial tear

Study type: Interventional

Funder types: Other

Identifiers

NCT01349452

GAN2011

Details and patient eligibility

About

Ganciclovir ophthalmic gel delivers multiple advantages in the treatment and prophylaxis of herpetic keratitis and shows potential for effectiveness against other viral ocular infections. The majority of adenoviral conjunctivitis will resolve without damaging vision, however, the investigators have no way to determine which cases will progress to ocular complications such as corneal infiltrates and pseudomembranes. Our purpose is to evaluate the efficacy of the Ganciclovir gel 0.15% in preventing ocular complications after adenoviral conjunctivitis.

Enrollment: 33 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• onset of symptoms for five days or less
• eighteen years old or more
• not pregnant or breastfeeding
• be able to understand and sign the consent term

Exclusion criteria

• use of antibiotic or corticoid 30 days before
• monocular vision
• keratopathy or other ocular diseases

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

33 participants in 2 patient groups

Ganciclovir

Experimental group

Treatment:

Drug: Ganciclovir

Artificial tear

Sham Comparator group

Treatment:

Drug: Artificial tear